Recent Updates — RNA

Atrium Therapeutics announced the dosing of the first patient in its Phase 1/2 Corventis clinical trial evaluating ATR 1072, a lead investigational therapy targeting PRKAG2 syndrome. The open-label study will enroll approximately 37 participants to assess safety and efficacy. Initial proof-of-concept data is expected in the second half of 2027. Atrium Therapeutics operates as a biopharmaceutical company advancing precision cardiology through targeted RNA therapeutics.

Atrium Therapeutics filed an amendment to a previous current report to correct the number of shares outstanding following its private placement offering. The company sold 5,170,384 shares of common stock and pre-funded warrants for up to 1,134,930 additional shares to accredited investors. Following the transaction, which includes shares issued for make whole equity awards related to its spin-off from Avidity Biosciences, the company has 21,571,507 shares outstanding. The filing corrects a previously disclosed figure but does not alter the terms of the offering or the capital raised. Atrium Therapeutics operates in the biotechnology industry, focusing on developing RNA-based therapeutics.

Atrium Therapeutics entered into a securities purchase agreement to sell 5,170,384 shares of common stock at $7.93 per share and pre-funded warrants for up to 1,134,930 additional shares at $7.929 each. The private placement is expected to generate approximately $50 million in gross proceeds before fees. Closing is anticipated on or about October 9, 2026. Proceeds will fund the development of lead product candidates and general corporate purposes, extending the company's cash runway through 2028. Atrium Therapeutics operates as a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart.

Atrium Therapeutics reported second quarter 2026 financial results on August 13, 2026. The company earned a $15 million milestone payment from Bristol Myers Squibb under their global cardiovascular collaboration and recognized $3.0 million in collaboration revenue primarily related to R&D services. For the quarter ended June 30, 2026, research and development expenses were $15.3 million and general and administrative expenses were $10.3 million, resulting in a net loss of approximately $20.2 million. As of June 30, 2026, the company held $263.9 million in cash, cash equivalents, and short-term investments, which management believes is sufficient to fund operations through mid-2028. The filing also highlighted FDA clearance for the IND application for ATR 1072 and the launch of the Corventis Phase 1/2 trial in PRKAG2 syndrome. Atrium Therapeutics operates as a biopharmaceutical company developing RNA therapeutics targeted to the heart.

Atrium Therapeutics, Inc. announced on July 14, 2026, that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ATR 1072, allowing the company to proceed with its Corventis™ Phase 1/2 clinical trial for treating Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. Atrium Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for genetic disorders.